Future Studies
Research, development, validation, and cost-effectiveness studies are ongoing to inform the best practices for detecting HCV viremia and for distinguishing between resolved HCV infection and biologic false positivity for HCV antibody in persons in whom HCV RNA is not detected. Outcomes of these studies will provide comprehensive guidance on testing, reporting, and clinical management, and will improve case definitions for disease notification and surveillance.
Morbidity and Mortality Weekly Report. 2013;62(18):362-365. © 2013
Centers for Disease Control and Prevention (CDC)
Comments